FORM 27

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER SECTION 85 (1) OF THE ACT

NOTE: This form is intended as a guideline. A letter or other document may be used if the substantive requirements of this form are complied with.

NOTE: Every report required to be filed under section 85 (1) of the Act shall be sent to the Commission in an envelope addressed to the Commission and marked "Continuous Disclosure."

NOTE: WHERE THIS REPORT IS FILED ON A CONFIDENTIAL BASIS PUT AT THE BEGINNING OF THE REPORT IN BLOCK CAPITALS "CONFIDENTIAL - SECTION 85" AND EVERYTHING THAT IS REQUIRED TO BE FILED SHALL BE PLACED IN AN ENVELOPE ADDRESSED TO THE SECRETARY OF THE COMMISSION MARKED "CONFIDENTIAL."

Item 1 *Reporting Issuer*
Biomax Technologies Inc.
568-999 Canada Place
Vancouver, BC V6C 3E1

Item 2 *Date of Material Change*

March 14, 2000

Item 3 *Press Release*

The Issuer issued a press release under date of March 14, 2000 via Canadian Corporate News, a copy of which is attached.

Items 4 & 5 Summary and Full Description of Material Change
Summary: BIOMAX TECHNOLOGIES INC. ANNOUNCES INCREASE OF $3.0 MILLION PRIVATE PLACEMENT TO $5.0 MILLION; CORRECTION OF WARRANT EXERCISE PRICE. *Full Description:* Further to the news release dated March 1, 2000, Biomax Technologies Inc. ("Biomax," the "Company"), at the request of its underwriting group, Haywood Securities Inc., Canaccord Capital Corporation and Pacific International Securities Inc., has received The Canadian Venture Exchange's approval to increase its private placement offering from $3 million to $5 million. The underwriting group made the request due to unanticipated high demand for the Special Warrants. The increased offering will be a private placement of 4 million Special Warrants (increased from 2.4 million Special Warrants), at a price of CDN$1.25 per Special Warrant, for total gross proceeds to the Company of CDN$5 million. The agents' commissions include 8.5% of the gross proceeds and Agent's Warrants representing 12% of the offering, each Agent's Warrant convertible into one common share and one-half share purchase warrant.

Each Special Warrant will entitle the holder to acquire, upon exercise, one common share of the Company and one-half of one share purchase warrant. Each full warrant will be exercisable into common shares of the Company at an exercise price of $1.50 per share for a period of one year. The warrant exercise price is changed from $1.25 to $1.50 per share, pursuant to the Exchange's policy.

The Special Warrants will be convertible at the time the Company files a prospectus with the applicable regulatory authorities. Concurrent with the filing of a prospectus, the Company plans to conduct a fully marketed prospectus offering of CDN$3.0 million in the form of Units, each Unit consisting of one common share and one-half share purchase warrant, at the then market price.

Item 6 *Reliance on Section 85(2) of the Act*

This report is not being filed on a confidential basis.

Item 7 *Omitted Information*

Not Applicable

Item 8 *Senior Officers*

To obtain further information, contact Brian Lock of the Issuer at (604) 688-7035.

Item 9 *Statement of Senior Officer*

The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, B.C., this 14th day of March, 2000.

SIGNATURE "*Brian Lock*"

NAME Brian Lock

TITLE Chairman & Director
(must be a senior officer)

It is an offence for a person to make a statement in a document required to be filed or furnished under the Act or the Regulation that at the time and in the light of the circumstances under which it is made, is a misrepresentation.

Instructions to Complete Form 27

1. State the full name and address of the principal office in Canada of the reporting Issuer.

2. Date of Material Change

3. State the date and place(s) of issuance of the press release issued pursuant to Section 67(1) of the Act.

4. Provide a brief but accurate summary of the nature and substance of the material change.

5. Supplement the summary required under Item 4 with the disclosure which should be sufficiently complete to enable a reader to appreciate the significance of the material change without reference to other material. Management is in the best position to determine what facts are significant and must disclose those facts in a meaningful manner. See also Item 7.

   This description of the significant facts relating to the material change will therefore include some or all of the following: dates, parties, terms and conditions, description of any assets, liabilities or capital affected, purpose, financial or dollar values, reasons for the change, and a general comment on the probable impact on the reporting issuer or its subsidiaries. Specific financial forecasts would not normally be required to comply with this form.

   The above list merely describes examples of some of the facts which may be significant. The list is not intended to be inclusive or exhaustive of the information required in any particular situation.

6. If the report is being filed on a confidential basis, state reason for reliance on section 67(2) and refer to section 67(3) concerning continuing obligations in respect of reports filed pursuant to this subsection.

7. In certain circumstances where a material change has occurred and a material change report has been or is about to be filed but section 67(3) of the Act will no longer or will not be relied upon, a reporting issuer may nevertheless believe one or more significant facts otherwise required to be disclosed in the material change report should remain confidential and not be disclosed in full detail in the material change report.

   State whether any information has been omitted on this basis and provide the reasons for any such omission in sufficient detail to permit the Commission to exercise its discretion pursuant to section 169(4) of the Act.

   The reasons for the omission may be contained in a separate letter filed as provided in section 151 of the Rules.

- To facilitate any necessary follow-up by the Commission, give the name and business telephone number of a senior officer of the reporting issuer who is knowledgeable about the material change and the report or an officer through whom such senior officer may be contacted by the Commission.

BIOMAX TECHNOLOGIES INC. (BIX.CDNX)

Release No.: 2000-09	***FOR IMMEDIATE RELEASE***

March 14, 2000 – Vancouver, BC, Canada – Further to the news release dated March 1, 2000, Biomax Technologies Inc. ("Biomax," the "Company"), at the request of its underwriting group, Haywood Securities Inc., Canaccord Capital Corporation and Pacific International Securities Inc., has received The Canadian Venture Exchange's approval to increase its private placement offering from $3 million to $5 million. The underwriting group made the request due to unanticipated high demand for the Special Warrants. The increased offering will be a private placement of 4 million Special Warrants (increased from 2.4 million Special Warrants), at a price of CDN$1.25 per Special Warrant, for total gross proceeds to the Company of CDN$5 million. The agents' commissions include 8.5% of the gross proceeds and Agent's Warrants representing 12% of the offering, each Agent's Warrant convertible into one common share and one-half share purchase warrant.

Each Special Warrant will entitle the holder to acquire, upon exercise, one common share of the Company and one-half of one share purchase warrant. Each full warrant will be exercisable into common shares of the Company at an exercise price of $1.50 per share for a period of one year. The warrant exercise price is changed from $1.25 to $1.50 per share, pursuant to the Exchange's policy.

The Special Warrants will be convertible at the time the Company files a prospectus with the applicable regulatory authorities. Concurrent with the filing of a prospectus, the Company plans to conduct a fully marketed prospectus offering of CDN$3.0 million in the form of Units, each Unit consisting of one common share and one-half share purchase warrant, at the then market price.

The proceeds of the proposed financing will be used to fund research and development, marketing and general working capital requirements. This proposed offering is subject to receipt of necessary approvals from the CDNX and other regulatory authorities. The final terms of the proposed offering may vary from the foregoing following approval by the CDNX.

Biomax Technologies Inc. is a Vancouver, BC-based medical device company developing optically based technologies for the treatment and diagnosis of a wide range of disease states including cancer and organ rejection. Biomax is listed on the Canadian Venture Exchange under the symbol "BIX."

On Behalf of the Board of Directors of
Biomax Technologies Inc.:

"Brian Lock"

Brian Lock
Chairman

FOR MORE INFORMATION PLEASE CONTACT:
Jonathan Burke, Manager, Shareholder Communications
Tel: (604) 638-2770 Ext: 106
Fax: (604) 638-2771
Brian Lock, Chairman
Tel: (604) 688-7035
Email: investor@biomax.com
Web: www.biomax.com

The statements made in this press release may contain certain forward-looking comments. Actual events or results may differ from the Company's expectations. No assurances can be given that the Company will be able to complete the development of its products. In addition to the matters described in the press release, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in various countries, results of pending or future clinical trials, as well as risk factors in the Company's SEC reports, may affect the actual results achieved by the Company. Exemption from registration pursuant to Rule 12g3-2(b), File No. 0-30184.The Canadian Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.